• Center on Health Equity & Access
  • Clinical
  • Health Care Cost
  • Health Care Delivery
  • Insurance
  • Policy
  • Technology
  • Value-Based Care

Questions for Medicare in Meningitis Outbreak

Article

Medicare is coming under scrutiny in the meningitis outbreak that has rekindled doubts about the safety of the nation's drug supply.

The giant health insurance program for seniors long ago flagged compounded drugs produced for the mass market without oversight from the Food and Drug Administration as safety risks. In 2007, Medicare revoked coverage of compounded inhaler drugs for lung disease.

Read the full story: http:/bit.ly/OQziq3

Source: The Associated Press

Related Videos
Eleanor Perfetto, PhD
Tom Kim, chief medical officer, Sound Long-Term Care Management
Ciara Zachary, PhD, MPH
William Schpero, PhD, MPhil, MPH
Jonathan Strober, MD, Benioff Children's Hospital
Adam Brufsky, MD, PhD
Ciara Zachary, PhD, MPH
Dr Xiaoxi Zhao
Related Content
Semaglutide | Image Credit: © Zimmy - stock.adobe.com

GoodRx to Match Novo Nordisk Price for Oral Semaglutide

January 5th 2026
Article

GoodRx offers affordable access to oral semaglutide for weight loss through telemedicine, simplifying treatment options and pricing for consumers.

Read More

2026 Health Care Predictions: AI, GLP-1s, MAHA, DEI: Sachin H. Jain, MD, MBA

2026 Health Care Predictions: AI, GLP-1s, MAHA, DEI: Sachin H. Jain, MD, MBA

January 1st 2026
Podcast

Sachin H. Jain, MD, MBA, discusses 2026 health care predictions, including AI adoption, GLP-1 demand, MAHA growth, DEI’s return, and policy shifts.

Listen

Highlights From Asembia 2025

ICYMI: Highlights From Asembia’s AXS25 Summit

December 31st 2025
Article

AI revolutionizes pharmacy by automating workloads, enhancing patient care, and navigating drug pricing challenges amid evolving federal policies.

Read More

managed care cast logo

Switching From MA to TM Increases Mental Health Care Use: Angela Liu, PhD, MPH

December 23rd 2025
Podcast

Angela Liu, PhD, MPH, speaks about her study that examined mental health care use by Medicare beneficiaries before and after switching from MA to TM.

Listen

Explore AJMC’s top 5 obesity insights of 2025, covering GLP-1 therapy trends, access, costs, and strategies to improve patient care.

Top 5 Most-Read Obesity Content of 2025

December 30th 2025
Article

Our top 5 obesity articles of 2025 highlight GLP-1 prescribing trends, insurance coverage, co-pay caps, real-world use, and access challenges.

Read More

The top 5 reimbursement content of 2025

Top 5 Most-Read Reimbursement Content of 2025

December 28th 2025
Article

The most-viewed content focused on the “One Big Beautiful Bill,” the Most Favored Nation drug policy, and other changes under the Trump administration.

Read More

© 2026 MJH Life Sciences
AJMC®
All rights reserved.